ArticleJournal of nanobiotechnology2026
Selenium-doped carbon dots nanozymes hitchhiking tailored liposomes block neuronal pyroptosis through GPX4/ROS/NLRP3/GSDMD axis to attenuate ischemic stroke.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vesicle-Mediated Delivery of Carbon Dots: Synthesis, Properties, and Biomedical Applications.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Ischemia-reperfusion (I/R) injury is a critical contributor to adverse outcomes following stroke. During I/R injury, excessive production of reactive oxygen species (ROS) leads to various forms of neuronal cell death. Moreover, the blood-brain barrier (BBB) significantly hinders the delivery and efficacy of many neuroprotective agents. Given selenium's crucial role in mitigating brain ischemia, we developed a selenium-based nanozyme encapsulated in glutathione (GSH)-conjugated liposomes to overcome these challenges. Specifically, we encapsulated selenium-doped carbon dot nanozymes (Se-CDs) within GSH-conjugated liposomes (Se-CD@LP-GSH) to enable targeted delivery and enhance therapeutic efficacy in ischemic stroke. This system demonstrates effective ROS scavenging capabilities both in vitro and in vivo, while also enhancing the biocompatibility of Se-CDs and their ability to cross the BBB. In the tMCAo model, Se-CD@LP-GSH reduces the neuronal death and infarct area following cerebral I/R injury, and promotes improvements in spatial learning ability and sensorimotor function. Mechanistically, Se-CD@LP-GSH promoted the upregulation of GPX4, an essential selenoprotein, thereby preserving mitochondrial function and suppressing ROS generation Consequently, the reduced ROS levels inhibit NLRP3/GSDMD-mediated neuronal pyroptosis during cerebral I/R injury. By improving the brain-targeting ability of Se-CDs via GSH-functionalized liposomal delivery, our work elucidates their neuroprotective efficacy and mechanistic basis, thus providing a translationally relevant strategy for ischemic stroke therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.